While these two cellular processes appear to be commonly implicated in ALS pathology and actively participate in disease progression [11,25], our results highlight HDAC inhibition as a relevant potential therapeutic strategy to treat this devastating disease. This evidence concerns the gene HDAC9 and amyotrophic lateral sclerosis.